Titanium Dioxide in Medicines: The Road Ahead
October 1, 2025
When Europe considered banning titanium dioxide in medicines, the pharma world braced for upheaval. With its short-term future in medicines secured, what’s next?
4 min read
False
October 1, 2025
When Europe considered banning titanium dioxide in medicines, the pharma world braced for upheaval. With its short-term future in medicines secured, what’s next?
4 min read
October 1, 2025
This webinar delves into the cutting-edge intersection of chemistry and biology, showcasing how targeted molecular innovation is driving the next generation of life science and diagnostics products.
10:00 am - 11:00 am GMT-4 min read
By Brian Carothers
September 24, 2025
As oligonucleotides gain traction, manufacturing capabilities and analytical systems are being retooled to meet new demands for scale, purity, and efficiency.
5 min read
By Christine Allen
September 23, 2025
In the age of automation and AI, here’s how pharma formulation will benefit.
6 min read
By Stephanie Vine
September 2, 2025
Researchers develop new tool for evaluating API stability under various conditions.
2 min read
September 2, 2025
The future of biologics is high-dose, low-volume, and delivery via patient centric devices. But developing stable formulations for these high-concentration biologics comes with challenges.
6 min read
September 1, 2025
Orbital experiments are tackling formulation problems, testing monoclonal antibodies, and changing how we think about drug development and crystallization.
4 min read
August 26, 2025
The EMA has maintained its faith in the safe use of titanium dioxide for pharmaceutical applications, but suggests that companies should look into alternatives.
2 min read
August 22, 2025
Early API development can drive environmental gains without sacrificing speed or yield.
8 min read
By Marwan Alsarraj
August 21, 2025
RNA therapeutics are advancing rapidly, but their clinical success depends on the availability of precise, reliable analytical methods.
11 min read
False
False
False